Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3%

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report)’s stock price fell 4.3% during mid-day trading on Monday . The company traded as low as $11.86 and last traded at $11.89. 20,523 shares were traded during trading, a decline of 74% from the average session volume of 80,120 shares. The stock had previously closed at $12.43.

Gyre Therapeutics Trading Down 2.9 %

The business has a fifty day moving average of $12.25 and a 200-day moving average of $16.08.

Gyre Therapeutics (NASDAQ:GYREGet Free Report) last released its earnings results on Thursday, May 9th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $27.17 million for the quarter. Analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insiders Place Their Bets

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total transaction of $282,600.00. Following the sale, the director now owns 1,636 shares in the company, valued at approximately $23,116.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 2.92% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

Further Reading

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with's FREE daily email newsletter.